首页> 外文期刊>Contrast media & molecular imaging >Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model
【24h】

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model

机译:在三阴性乳腺癌模型中,Debio 1143(细胞凋亡蛋白(IAP)的多种抑制剂的拮抗剂)的药效学作用的核成像研究。

获取原文
           

摘要

Background. Debio 1143, a potent orally available SMAC mimetic, targets inhibitors of apoptosis proteins (IAPs) members and is currently in clinical trials. In this study, nuclear imaging evaluated the effects of Debio 1143 on tumor cell death and metabolism in a triple-negative breast cancer (TNBC) cell line (MDA-MB-231)-based animal model. Methods. Apoptosis induced by Debio 1143 was assessed by FACS (caspase-3, annexin 5 (A5)), binding of 99mTc-HYNIC-Annexin V, and a cell proliferation assay. 99mTc-HYNIC-Annexin V SPECT and [18F]-FDG PET were also performed in mice xenografted with MDA-MB-231 cells. Results. Debio 1143 induced early apoptosis both in vitro and in vivo 6 h after treatment. Debio 1143 inhibited tumor growth, which was associated with a decreased tumor [18F]-FDG uptake when measured during treatment. Conclusions. This imaging study combining SPECT and PET showed the early proapoptotic effects of Debio 1143 resulting in a robust antitumor activity in a preclinical TNBC model. These imaging biomarkers represent valuable noninvasive tools for translational and clinical research in TNBC.
机译:背景。 Debio 1143是一种有效的口服SMAC模拟物,靶向凋亡蛋白(IAP)成员的抑制剂,目前正在临床试验中。在这项研究中,核成像评估了基于三阴性乳腺癌(TNBC)细胞系(MDA-MB-231)的动物模型中Debio 1143对肿瘤细胞死亡和代谢的影响。方法。通过FACS(caspase-3,膜联蛋白5(A5)),99mTc-HYNIC-Annexin V的结合以及细胞增殖试验评估了Debio 1143诱导的细胞凋亡。还用异种移植了MDA-MB-231细胞的小鼠进行了99mTc-HYNIC-Annexin V SPECT和[18F] -FDG PET。结果。 Debio 1143在治疗后6h内和体外均可诱导早期凋亡。 Debio 1143抑制肿瘤生长,在治疗期间进行测量可发现肿瘤[18F] -FDG摄取减少。结论。这项结合SPECT和PET的影像学研究表明Debio 1143的早期促凋亡作用在临床前TNBC模型中产生了强大的抗肿瘤活性。这些成像生物标记物代表TNBC中有价值的非侵入性工具,用于翻译和临床研究。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号